上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受深圳市卫光生 物制品股份有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 年 第一次临时股东大会（以下简称"本次股东大会"），并根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"） 等法律、法规和规范性文件以及现行有效的《深圳市卫光生物制品股份有限公司 章程》（以下简称"《公司章程》"）的相关规定，对本次股东大会相关法律事 项进行见证并出具本法律意见书 ...

2025 年第一次临时股东大会决议公告 证券代码:002880 证券简称:卫光生物 公告编号:2025-026 深圳市卫光生物制品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东大会召开期间无否决议案的情况； 2.本次股东大会未涉及变更以往股东大会已通过议案的情况。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议：2025 年 7 月 17 日 14:30。 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 7 月 17 日 9:15–9:25、9:30–11:30、13:00–15:00；通过深圳证券交易所互联网投票系 统投票的时间为 2025 年 7 月 17 日 9:15 至 15:00。 2.现场会议召开地点：广东省深圳市光明区光明街道光侨大道 3402 号公司办公 楼 4 楼会议室。 3.会议召开方式：现场投票和网络投票相结合。 4.会议召集人：公司董事会。 5.会议的召集、召开符合《公司法》《上市公司股东会规则》《公司章程》等的 规定。 本次股东大会以 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-025 深圳市卫光生物制品股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）2024 年度权益分派方案已经 2025 年 5 月 19 日召开的 2024 年度股东大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 3.本次利润分配方案按照分配总额不变的原则实施。 4.本次实施分配方案距离股东大会审议通过的时间未超过两个月。 二、权益分派方案 本公司 2024 年度权益分派方案为：以公司现有总股本 226,800,000 股为基数，向 全体股东每 10 股派发现金红利 2.00 元（含税；扣税后，通过深股通持有股份的香港 市场投资者、境外机构（含 QFII、RQFII）以及持有首发前限售股的个人和证券投资 基金每 10 股派 1.80 元；持有首发后限售股、股权激励限售股及无限售流通股的个人 股息红利税实行差别化税率征收，本公司暂不扣缴个人所得税，待个人转让股票时， 根据其持股期限 ...

Group 1: Plasma Source and Quality Control - The company implements a strategy of incremental cultivation and potential excavation for plasma source development, setting annual plasma collection targets based on previous year's data and company strategy [2] - A comprehensive blood plasma quality management system has been established, with a strong emphasis on digital regulatory system construction to ensure the safety of raw plasma quality [2] - The "Pingguo Experience" is a long-term accumulated work experience that optimizes the entire plasma collection process, which is promoted across other plasma stations to enhance service levels [2] Group 2: Plasma Collection Stations and Growth - The company currently operates 9 plasma collection stations, with a sustained growth in plasma collection scale in recent years [3] - The average plasma collection volume at the stations is leading in the industry, with the Pingguo station showing continuous growth [3] - The company holds 11 product varieties across 3 major categories, achieving a high comprehensive utilization rate of plasma [3] Group 3: Market Position and Strategic Response - The blood product market in China still has significant growth potential compared to mature markets in Europe and the U.S., despite challenges from recombinant products [4] - The company plans to enhance R&D capabilities to introduce more new products, maintaining a focus on traditional blood-derived products [4] - The company actively monitors industry dynamics to identify new profit growth points while solidifying its core blood product business [3] Group 4: Research and Development Projects - Recent achievements include obtaining registration certificates for human coagulation factor VIII and prothrombin complex, with ongoing key projects in various blood-related products [4] - R&D investment is determined based on strategic planning and project progress, ensuring effective allocation of resources [4] Group 5: Market Share and Brand Competitiveness - The company adopts market-oriented sales strategies tailored to different products, continuously improving its marketing system and building a professional sales team [4] - Efforts are made to expand new sales channels while deepening cooperation with relevant parties to enhance international visibility and brand influence [4]

Group 1 - The company has nominated Huang Juan as an independent director candidate for its fourth board of directors, confirming her independence and compliance with relevant regulations [1][2][3] - Huang Juan has undergone qualification review by the company's nomination committee and has no relationships that could affect her independent performance [1][2] - The candidate has confirmed that she meets the qualifications and conditions set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange for independent directors [2][3][4] Group 2 - The company has also nominated Zhang Jianping as an independent director candidate, who has agreed to the nomination and confirmed his independence [29][58] - Zhang Jianping has passed the qualification review and has no conflicts of interest that could impact his independent duties [29][58] - The nomination is based on a thorough understanding of Zhang Jianping's professional background, qualifications, and absence of any significant credit issues [29][58]

Core Viewpoint - Shenzhen Weiguang Biological Products Co., Ltd. is undergoing a board re-election process in accordance with relevant laws and regulations, with the nomination of candidates for the fourth board of directors [1][2]. Group 1: Board Election Process - The third board of directors held its thirty-fourth meeting on July 1, 2025, and approved the proposals for the re-election of the board and the nomination of candidates for both non-independent and independent directors [2]. - The candidates for the fourth board include five non-independent directors and three independent directors, with their qualifications having been reviewed by the board's nomination committee [2][3]. - The election will be conducted at the company's first extraordinary general meeting of 2025, using a cumulative voting system to elect eight directors, alongside one employee representative director [2][3]. Group 2: Candidate Qualifications - Zhang Zhan, the current chairman, has a graduate degree and is a senior engineer, with a history of serving in various roles within the company [3][4]. - Guo Caiping, the current general manager, holds a doctoral degree and has been with the company since 1994, having held multiple positions [5][6]. - Chen Guanqun, the financial director, is a senior accountant with a bachelor's degree in economics and has experience in various financial roles [6][7]. - Li Ligan, a current director, has a bachelor's degree and serves as the financial director at another company [7][8]. - Zhang Xianen, a biotechnology expert, has extensive academic qualifications and has held significant positions in research institutions [8][9]. - The independent director candidates, including Wang Yanmei, Huang Juan, and Zhang Jianping, have relevant academic and professional backgrounds, ensuring they meet the independence criteria [9][10].

深圳市卫光生物制品股份有限公司 序号 修订前 修订后 第一条 为维护公司、股东和债权人的合法权益，规范公司的组 第一条 为维护公 司、股东、职工和债权人的合法权益，规范公司的组织和行 织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》） 《中 为，根据《中华人民共和国公司法》 （以下简称《公司法》） 《中华人民共和国证券法》 华人民共和国证券法》（以下简称《证券法》）《中国共产党章程》（以 （以下简称《证券 法》） 《中国共产党章程》（以下简称《党章》） 和其他有关规定， 下简称《党章》 ）和其他有关规定，制订本章程。 制订本章程。 第八条 董事长为公司的法定代表人。 董事长辞任的，视为同时辞去法定代表人。 董事长辞任或者不再担任法定代表人的，在选任新任 董事长之前，由总经理兼 法定代表人以公司名义从事的民事活动，其法律后果 由公司承受。本章程或者 股东会对法定代表人职权的限制，不得对抗善意相对 人。 担民事责任。公司承担民 的法定代表人追偿。 任，公司以其全部财产对公司 第九条 公司全部资产分为等额股份，股东以其认购的股份为限 对公司承担责任，公司以其全部资产对公司的债务承担责任。 第十四条 经依 ...

Core Viewpoint - Shenzhen Weiguang Biological Products Co., Ltd. has revised its Articles of Association and related systems to enhance corporate governance and operational standards [1][2]. Group 1: Articles of Association Revision - The company has proposed amendments to its Articles of Association to improve governance structure and comply with relevant laws and regulations [1]. - The revised Articles of Association and a comparison table of changes are available on the official website [1]. Group 2: Related System Revisions - The board of directors has approved revisions to several internal systems, including those related to independent directors, audit committee, nomination committee, compensation and assessment committee, strategic committee, insider information management, and accountant selection [1]. - The full text of the revised systems is also published on the official website [1].

Core Points - The company has approved the implementation of the third employee stock ownership plan [1][2] - The lock-up period for the employee stock ownership plan will expire on July 7, 2025 [1] - The plan has completed the purchase of company shares through the secondary market as of July 3, 2024 [1] Summary of Employee Stock Ownership Plan - The employee stock ownership plan will have a lock-up period of 12 months from the date of the last share transfer [1] - After the lock-up period, the management committee will decide on the timing of selling the shares held by the plan [1][2] - The plan will comply with market trading rules and relevant laws and regulations [1] Duration, Changes, and Termination of the Plan - The duration of the employee stock ownership plan starts from the date of the last share transfer to the plan [2] - Changes to the plan require approval from at least two-thirds of the participating holders [2] - The plan can be terminated early under certain conditions, including the inability to liquidate all shares before the expiration of the duration [2]

Core Viewpoint - The independent director candidate Wang Yanmei has declared her commitment and qualifications to serve on the fourth board of Shenzhen Weiguang Biological Products Co., Ltd, ensuring her independence and compliance with relevant regulations [1][2][3]. Group 1 - The candidate has confirmed that there are no relationships with the company that could affect her independence [1]. - The candidate has passed the qualification review by the company's nomination committee and has no conflicts of interest with the nominator [1]. - The candidate meets the qualifications and conditions for independent directors as stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange [1][2]. Group 2 - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2]. - The candidate has no violations of laws or regulations that would disqualify her from serving as an independent director [2][3]. - The candidate has the necessary knowledge and experience related to the operation of listed companies, with over five years of relevant work experience [3][4]. Group 3 - The candidate and her immediate family do not hold any shares in the company or its subsidiaries [4][5]. - The candidate has not been subject to any disqualifications or penalties by regulatory authorities in the past three years [5][6]. - The candidate has committed to report any changes in her qualifications during her tenure as an independent director [6][7].